Mueller Brian's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 38,590 Stock Option (Right to Buy Common Stock) done . Disclosure was reported to the exchange on March 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 38,590 | 38,590 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.44 per share. | 14 Mar 2025 | 18,497 | 83,141 (0%) | 0% | 69.4 | 1,284,432 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 16,640 | 99,781 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Sale of securities on an exchange or to another person at price $ 180.40 per share. | 01 Mar 2025 | 7,723 | 293,413 (0%) | 0% | 180.4 | 1,393,229 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 179.82 per share. | 01 Mar 2025 | 5,351 | 301,696 (0%) | 0% | 179.8 | 962,217 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Mar 2025 | 560 | 301,136 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 11,040 | 82,611 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,660 | 92,271 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller R. | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 9,367 | 101,638 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 7,014 | 307,047 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Sale of securities on an exchange or to another person at price $ 171.26 per share. | 12 Nov 2024 | 7,700 | 300,033 (0%) | 0% | 171.3 | 1,318,702 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.33 per share. | 28 Jun 2024 | 588 | 71,571 (0%) | 0% | 82.3 | 48,410 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.19 per share. | 30 May 2024 | 5,000 | 72,159 (0%) | 0% | 75.2 | 375,950 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 May 2024 | 5,000 | 0 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.10 per share. | 30 May 2024 | 5,000 | 77,159 (0%) | 0% | 63.1 | 315,500 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 68.65 per share. | 30 May 2024 | 300 | 72,159 (0%) | 0% | 68.6 | 20,594 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 25,540 | 25,540 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.87 per share. | 15 Mar 2024 | 20,789 | 71,859 (0%) | 0% | 83.9 | 1,743,573 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,400 | 92,648 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.71 per share. | 01 Mar 2024 | 5,661 | 307,733 (0%) | 0% | 134.7 | 762,593 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 20,220 | 66,343 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 8,802 | 75,145 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Mueller Brian | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 6,103 | 81,248 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | E. Brian Mueller | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 9,277 | 313,394 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Mueller Brian | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 66.88 per share. | 31 Dec 2023 | 318 | 46,123 (0%) | 0% | 66.9 | 21,267 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.93 per share. | 29 Jun 2023 | 4,602 | 50,983 (0%) | 0% | 88.9 | 409,256 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.93 per share. | 29 Jun 2023 | 4,602 | 46,381 (0%) | 0% | 88.9 | 409,256 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.93 per share. | 29 Jun 2023 | 576 | 45,805 (0%) | 0% | 88.9 | 51,224 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 21,970 | 21,970 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 9,630 | 62,266 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 93.41 per share. | 15 Mar 2023 | 3,973 | 55,585 (0%) | 0% | 93.4 | 371,118 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.74 per share. | 15 Mar 2023 | 2,708 | 59,558 (0%) | 0% | 87.7 | 237,600 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.65 per share. | 01 Mar 2023 | 5,867 | 304,117 (0%) | 0% | 113.7 | 666,785 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 12,660 | 40,406 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 10,980 | 51,386 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 1,250 | 52,636 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 10,732 | 309,984 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.10 per share. | 13 Jan 2023 | 2,500 | 30,246 (0%) | 0% | 63.1 | 157,750 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 2,500 | 5,000 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.50 per share. | 13 Jan 2023 | 2,500 | 27,746 (0%) | 0% | 114.5 | 286,250 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 107.50 per share. | 13 Dec 2022 | 2,500 | 27,746 (0%) | 0% | 107.5 | 268,750 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 63.10 per share. | 13 Dec 2022 | 2,500 | 30,246 (0%) | 0% | 63.1 | 157,750 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2022 | 2,500 | 7,500 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 3,761 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.50 per share. | 02 Dec 2022 | 3,761 | 27,746 (0%) | 0% | 104.5 | 393,025 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 02 Dec 2022 | 3,761 | 31,507 (0%) | 0% | 67.8 | 255,033 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 02 Dec 2022 | 2,139 | 29,885 (0%) | 0% | 67.8 | 145,046 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 2,139 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.50 per share. | 02 Dec 2022 | 2,139 | 27,746 (0%) | 0% | 104.5 | 223,526 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 104.50 per share. | 02 Dec 2022 | 1,101 | 27,746 (0%) | 0% | 104.5 | 115,055 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2022 | 3,500 | 3,761 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 99.50 per share. | 23 Nov 2022 | 3,500 | 28,847 (0%) | 0% | 99.5 | 348,250 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 23 Nov 2022 | 3,500 | 32,347 (0%) | 0% | 67.8 | 237,335 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 99.50 per share. | 23 Nov 2022 | 945 | 28,847 (0%) | 0% | 99.5 | 94,028 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 95.09 per share. | 23 Nov 2022 | 934 | 29,792 (0%) | 0% | 95.1 | 88,814 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 94.50 per share. | 05 Aug 2022 | 3,500 | 30,726 (0%) | 0% | 94.5 | 330,750 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2022 | 3,500 | 7,261 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.81 per share. | 05 Aug 2022 | 3,500 | 34,226 (0%) | 0% | 67.8 | 237,335 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.50 per share. | 08 Jul 2022 | 7,337 | 30,726 (0%) | 0% | 89.5 | 656,662 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.92 per share. | 29 Jun 2022 | 576 | 38,063 (0%) | 0% | 83.9 | 48,338 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2022 | 1,115 | 299,252 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 26,520 | 26,520 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 11,040 | 40,749 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.27 per share. | 15 Mar 2022 | 1,868 | 38,881 (0%) | 0% | 78.3 | 146,208 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.72 per share. | 15 Mar 2022 | 582 | 38,299 (0%) | 0% | 80.7 | 46,979 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.19 per share. | 01 Mar 2022 | 6,314 | 300,367 (0%) | 0% | 88.2 | 556,832 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.77 per share. | 03 Feb 2022 | 1,072 | 29,709 (0%) | 0% | 87.8 | 94,089 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 14,598 | 306,681 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.46 per share. | 29 Jun 2021 | 576 | 30,781 (0%) | 0% | 83.5 | 48,073 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 79.50 per share. | 30 Apr 2021 | 6,709 | 31,357 (0%) | 0% | 79.5 | 533,366 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 28.23 per share. | 30 Apr 2021 | 6,709 | 38,066 (0%) | 0% | 28.2 | 189,395 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2021 | 6,709 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 62.41 per share. | 30 Apr 2021 | 341 | 31,357 (0%) | 0% | 62.4 | 21,281 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.52 per share. | 22 Mar 2021 | 516 | 36,708 (0%) | 0% | 78.5 | 40,516 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 24,890 | 24,890 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 10,110 | 38,800 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.39 per share. | 15 Mar 2021 | 994 | 37,806 (0%) | 0% | 78.4 | 77,920 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.21 per share. | 15 Mar 2021 | 582 | 37,224 (0%) | 0% | 77.2 | 44,936 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.72 per share. | 01 Mar 2021 | 7,672 | 292,083 (0%) | 0% | 106.7 | 818,756 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Sale of securities on an exchange or to another person at price $ 108.63 per share. | 22 Feb 2021 | 70,000 | 299,755 (0%) | 0% | 108.6 | 7,604,100 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 70,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.34 per share. | 22 Feb 2021 | 70,000 | 369,755 (0%) | 0% | 15.3 | 1,073,800 | Common Stock |
| Biomarin Pharmaceutical In... | Brian Mueller | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.82 per share. | 03 Feb 2021 | 1,071 | 28,673 (0%) | 0% | 82.8 | 88,700 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 14,093 | 299,755 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Sale of securities on an exchange or to another person at price $ 90.41 per share. | 04 Jan 2021 | 20,000 | 285,662 (0%) | 0% | 90.4 | 1,808,200 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 20,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.34 per share. | 04 Jan 2021 | 20,000 | 305,662 (0%) | 0% | 15.3 | 306,800 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Dec 2020 | 565 | 285,662 (0%) | 0% | 0 | Common Stock | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.34 per share. | 01 Dec 2020 | 20,000 | 306,227 (0%) | 0% | 15.3 | 306,800 | Common Stock |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 20,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Grand Canyon Education Inc | Brian E. Mueller | Director, CEO | Sale of securities on an exchange or to another person at price $ 83.70 per share. | 01 Dec 2020 | 20,000 | 286,227 (0%) | 0% | 83.7 | 1,674,000 | Common Stock |